Future Treatments of NASH

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current Hepatology Reports

• Publication date

  2016-04-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11901-016-0300-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents

  2017cited by this paper
• Pathogenesis of Nonalcoholic Steatohepatitis.

  2016cited by this paper
• Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

  2016cited by this paper
• Energy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition

  2016cited by this paper
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

  2016cited by this paper
• Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis

  2016cited by this paper
• Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

  2015cited by this paper
• Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.

  2015cited by this paper
• Inflammasome activation and function in liver disease

  2015cited by this paper
• Genetic and functional characterization of clonally derived adult human brown adipocytes

  2015cited by this paper
• Clonal analyses and gene profiling identify genetic biomarkers of human brown and white preadipocyte thermogenic potential

  2015cited by this paper
• Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

  2015cited by this paper
• Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis.

  2015cited by this paper
• The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective.

  2015cited by this paper
• The pan‐caspase inhibitor Emricasan (IDN‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis

  2015cited by this paper
• Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats

  2015cited by this paper
• Thyroid hormone, thyromimetics, and metabolic efficiency.

  2014cited by this paper
• Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.

  2014cited by this paper
• The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.

  2014cited by this paper
• No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.

  2014cited by this paper
• Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis

  2013cited by this paper
• Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease.

  2013cited by this paper
• Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler.

  2013cited by this paper
• Peroxisome proliferator-activated receptor &dgr;: a multifaceted metabolic player

  2013cited by this paper
• Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors

  2013cited by this paper
• Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

  2013cited by this paper
• Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

  2012cited by this paper
• Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow‐up study

  2012cited by this paper
• Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.

  2012cited by this paper
• A phase 2, randomized, double‐blind, placebo‐controlled study of GS‐9450 in subjects with nonalcoholic steatohepatitis

  2012cited by this paper
• S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility.

  2012cited by this paper
• Uric Acid Stimulates Fructokinase and Accelerates Fructose Metabolism in the Development of Fatty Liver

  2012cited by this paper
• Activation of the Farnesoid X Receptor Induces Hepatic Expression and Secretion of Fibroblast Growth Factor 21*

  2012cited by this paper
• Brown adipose tissue activity controls triglyceride clearance

  2011cited by this paper
• Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

  2011cited by this paper
• Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial.

  2011cited by this paper
• Hepatic Lipid Peroxidation and Cytochrome P-450 2E1 in Pediatric Nonalcoholic Fatty Liver Disease and Its Subtypes

  2011cited by this paper
• Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo‐controlled trial

  2011cited by this paper
• Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis

  2011cited by this paper
• Hepatic FXR: key regulator of whole-body energy metabolism.

  2011cited by this paper
• Fatty liver and lipotoxicity.

  2010cited by this paper
• Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit

  2010cited by this paper
• Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism

  2010cited by this paper
• The role of the gut microbiota in nonalcoholic fatty liver disease

  2010cited by this paper
• Inflammatory lipid mediators in adipocyte function and obesity

  2010cited by this paper
• Novel Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease

  2010cited by this paper
• Dietary fructose exacerbates hepatocellular injury when incorporated into a methionine‐choline‐deficient diet

  2010cited by this paper
• Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

  2010cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010cited by this paper
• Role of bile acids and bile acid receptors in metabolic regulation.

  2009cited by this paper
• TGR5-mediated bile acid sensing controls glucose homeostasis.

  2009cited by this paper
• Dietary sucrose is essential to the development of liver injury in the methionine-choline-deficient model of steatohepatitis[S]

  2009cited by this paper
• Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial

  2009cited by this paper
• Reduction of hepatic steatosis in rats and mice after treatment with a liver‐targeted thyroid hormone receptor agonist

  2009cited by this paper
• Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease

  2008cited by this paper
• Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men

  2008cited by this paper
• A lipidomic analysis of nonalcoholic fatty liver disease

  2007cited by this paper
• FXR‐deficiency confers increased susceptibility to torpor

  2007cited by this paper
• Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention.

  2007cited by this paper
• Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis.

  2007cited by this paper
• Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis

  2007cited by this paper
• Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index

  2007cited by this paper
• Cholestasis and hypercholesterolemia in SCD1-deficient mice fed a low-fat, high-carbohydrate diets⃞ Published, JLR Papers in Press, September 28, 2006.

  2006cited by this paper
• Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

  2006cited by this paper
• Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

  2005cited by this paper
• Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

  2004cited by this paper
• Lipotoxicity: when tissues overeat

  2003cited by this paper
• Hepatic steatosis: Innocent bystander or guilty party?

  1998cited by this paper
• Steatohepatitis: a tale of two "hits"?

  1998cited by this paper

• Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases

  2018cites this paper
• STK 25 A new regulator of the risk of metabolic liver disease and cardiovascular disease risk

  2018cites this paper
• Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates

  2017cites this paper
• Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates

  2017cites this paper